In patients with isolated REM sleep behavior disorder, higher DTI-ALPS indices—indicative of better glymphatic function—were associated with longer prodromal symptom duration and substantially delayed phenoconversion to alpha-synucleinopathy.

Wearable inertial-sensor gait measures in idiopathic RBD patients—particularly stride length, swing time variability, and arm-swing metrics—were associated with later phenoconversion and preferentially predicted a parkinsonism-first trajectory, with converters showing steeper longitudinal decline…

This study reports that plasma neurofilament light chain is elevated in isolated REM sleep behavior disorder, correlates with neurogenic orthostatic hypotension, and may mark an autonomic-severe iRBD subgroup with greater risk of phenoconversion (notably to MSA).

This PSG study found that PD patients with levodopa-induced dyskinesia lack the normal overnight increase in cortical sample entropy during N3 sleep observed in controls, and that reduced overnight SampEn change correlates with dyskinesia severity.

A critical review summarizing the history, current status, and misconceptions of dopamine cell replacement therapy for Parkinson’s disease, from fetal grafts to stem cell-derived vmDA neuron transplants now entering clinical trials.

Narrative review synthesizing preclinical (mostly rodent) evidence that exercise-released exerkines—including BDNF, irisin, cathepsin B, IL-6, and IGF-1—modulate neurogenesis, synaptic plasticity and neuroinflammation and could underlie exercise’s benefits in neurodegenerative and mental disorders.

Clinical guideline addressing diagnosis and outpatient management of dysphagia in Parkinson's disease, recommending targeted history, FEES, and individualized multidisciplinary treatment (speech therapy, physiotherapy, occupational and respiratory therapy, nutritional support).

This review synthesizes evidence that dysfunctional Ca2+-storing organelles (endoplasmic reticulum, mitochondria, lysosomes) and their interconnections drive neurodegeneration and highlights specific interventions—modulating mitochondrial Ca2+ handling at mitochondria-associated membranes/MCU,…

Using genome-scale metabolic models and the TAMBOOR algorithm, the study predicts patient-specific metabolite secretion changes in Parkinson’s disease, identifies consensus and cluster-specific biomarkers (including dopamine, salsolinol, vitamin D3, retinal, melatonin, biliverdin), and stratifies…

In LPS/TNF-α-induced mouse and SH-SY5Y cell PD models, biochanin A reduced lipid peroxidation, improved iron and antioxidant balance, and rescued behavioral and cellular deficits by inhibiting ferroptosis via the Sirt1/Nrf2/GPX4 signaling axis, with pathway involvement probed using ML385 and EX527.

This review proposes that striatal parvalbumin interneurons (PVINs) — early integrators of dopaminergic, inflammatory, and network signals and a principal source of striatal GDNF — undergo a compensatory-to-degenerative shift that promotes maladaptive synaptic plasticity in Parkinson's disease and…

Systematic review and meta-analysis of 13 randomized trials (557 patients) finding apomorphine—especially intermittent subcutaneous injection—significantly improves motor symptoms and reduces OFF time in Parkinson’s disease versus placebo, at the cost of increased mild-to-moderate adverse events.

This review compiles preclinical evidence that the isothiocyanate erucin, a compound from cruciferous vegetables, may protect neurons via antioxidant, anti-inflammatory, and neurotrophic mechanisms and summarizes limited pharmacokinetic and model data with tentative relevance to AD and PD.

This Perspective presents the alpha-synuclein proximity ligation assay (αSYN-PLA) that reveals widespread, non-inclusion oligomeric α-synuclein pathology—including in LB-negative LRRK2 PD—and discusses antibody strategies, structural implications, temporal dynamics, and clinical applications as…

Mechanistic review focusing on how disruptions of the synaptic vesicle trafficking cycle—driven in PD by alpha-synuclein aggregation and LRRK2-Rab trafficking defects—contribute to presynaptic dysfunction and summarizes mechanism-oriented therapeutic strategies.

This review reframes age-related neurodegeneration as driven by heterotypic co-aggregation of amyloidogenic proteins (α-synuclein, tau, Aβ, TDP-43), synthesizing biophysical, cellular, animal, and human data on cross-seeding and shared vulnerability pathways and highlighting translational…

This review synthesizes current knowledge of mitochondria-derived vesicles (MDVs) as a distinct mitochondrial quality control pathway—covering MDV biogenesis, trafficking, clearance, roles in inter-organelle signaling and intercellular communication—and links MDV dysfunction to Parkinson's disease…

Review of technical advances, validation, and clinical application of tau and α-synuclein PET tracers—highlighting second-generation tau tracers (e.g., [18F]PI-2620) and emerging α-synuclein tracer [18F]ACI-12589—that improve differentiation of atypical parkinsonian syndromes.

The authors developed an explainable machine-learning survival model and integer risk score using baseline clinical, autonomic, cognitive and mood measures in de novo PD patients to predict long-term progression of depression (test C-index 0.744) and stratify patients into low/moderate/high risk.

Targeted review of Parkinson's disease–related fatigue that highlights preliminary evidence for rTMS and tDCS reducing fatigue and improving cognitive processing but notes small sample sizes, heterogeneous protocols, and limited standardized outcomes.